NICE guidance - exenatide
NICE guidance states that a GLP-1 mimetic (incretin mimetic) (exenatide) is a therapeutic option in type 2 diabetes.
In the latest guidance (2) NICE state that:
If triple therapy (metformin tolerant treatment arm) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, an SU and a GLP-1 mimeticc for adults with type 2 diabetes who:
- have a BMI of 35 kg/m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or
- have a BMI lower than 35 kg/m2, and for whom insulin therapy would have significant occupational implications, or weight loss would benefit other significant obesity-related comorbidities
Continuation of GLP-1
- Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol/mol [1.0%] in HbA1c and a weight loss of at least 3% of initial body weight in 6 months)
For detailed guidance then consult the full guideline (2).
Reference:
Related pages
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.